Paul T. Conway
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paul T. Conway has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Edward V. Hickey
American Association of Kidney Patients, Tampa, Florida
3 shared publications - Glenda V. Roberts
Icahn School of Medicine at Mount Sinai, New York, New York
2 shared publications - Glenn M. Chertow
Stanford University School of Medicine
2 shared publications - Kaleab Z. Abebe
Department of Medicine, University of Pittsburgh, Pittsburgh, USA
2 shared publications Kathleen D. Liu
Medicine and Anesthesia, University of California, San Francisco, San Francisco, California
2 shared publications- Mark David Lim
Kidney Health Initiative, American Society of Nephrology, Washington, DC
2 shared publications
Latest Publications
- 28 April 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (7) , 1608-1610
In Memoriam of Dr. Murray I. Sheldon
An abstract is unavailable. This article is available as a PDF only.
- 28 April 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (7) , 1608-1610
In Memoriam of Dr. Murray I. Sheldon
An abstract is unavailable. This article is available as a PDF only.
- 17 February 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (11) , 2041-2050
National Institutes of Health Workshop to Accelerate Therapeutic Innovation by Optimizing Kidney Precision Medicine Clinical Trials
The National Institute of Diabetes and Digestive and Kidney Diseases sponsored a scientific workshop in 2024, titled “Preparing for Kidney Precision Medicine Clinical Trials.” The purpose of the workshop was to gain a better understanding of the therapeutic journey of patients with kidney disease and define candidate indicators for precision medicine strategies, targets, and trial readiness. Workshop participants were tasked with identifying best practices, opportunities, and barriers to kidney precision medicine clinical trials, with a shared goal to optimize the design and conduct of these trials. The patient perspective served as a foundation for the meeting. Trial design should be flexible, dynamic, responsive to transitions in patient care and minimize fragmentation of care. The value of understanding mechanisms and defining endophenotypes and targets to facilitate new therapeutic approaches was discussed with examples presented for acute and CKDs. The importance of biomarkers for diagnosis and evaluation of therapeutic response was emphasized. Laboratory and assay considerations for precision medicine trials were discussed with examples of successful large precision medicine trials supported by laboratory networks presented. There was discussion of the barriers to precision trials in nephrology, including suboptimal patient engagement, precision trial expertise, infrastructure, and financial resources. Engagement in demonstration projects to test the ability of various approaches to expedite the right treatment to the right patient was highlighted. Of utmost importance is the better design of clinical trials which consider differences in genetics and status of disease mechanisms to validate individual patient-focused innovative and effective precision therapeutic approaches.
- 17 February 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (11) , 2041-2050
National Institutes of Health Workshop to Accelerate Therapeutic Innovation by Optimizing Kidney Precision Medicine Clinical Trials
The National Institute of Diabetes and Digestive and Kidney Diseases sponsored a scientific workshop in 2024, titled “Preparing for Kidney Precision Medicine Clinical Trials.” The purpose of the workshop was to gain a better understanding of the therapeutic journey of patients with kidney disease and define candidate indicators for precision medicine strategies, targets, and trial readiness. Workshop participants were tasked with identifying best practices, opportunities, and barriers to kidney precision medicine clinical trials, with a shared goal to optimize the design and conduct of these trials. The patient perspective served as a foundation for the meeting. Trial design should be flexible, dynamic, responsive to transitions in patient care and minimize fragmentation of care. The value of understanding mechanisms and defining endophenotypes and targets to facilitate new therapeutic approaches was discussed with examples presented for acute and CKDs. The importance of biomarkers for diagnosis and evaluation of therapeutic response was emphasized. Laboratory and assay considerations for precision medicine trials were discussed with examples of successful large precision medicine trials supported by laboratory networks presented. There was discussion of the barriers to precision trials in nephrology, including suboptimal patient engagement, precision trial expertise, infrastructure, and financial resources. Engagement in demonstration projects to test the ability of various approaches to expedite the right treatment to the right patient was highlighted. Of utmost importance is the better design of clinical trials which consider differences in genetics and status of disease mechanisms to validate individual patient-focused innovative and effective precision therapeutic approaches.
- Open Access
- 11 April 2025
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 32 (2) , 154-161
Postdischarge Care of Acute Kidney Injury Survivors: An Opportunity for Targeted Nurse and Pharmacist Interventions
- 11 April 2025
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 32 (2) , 154-161
Open AccessPostdischarge Care of Acute Kidney Injury Survivors: An Opportunity for Targeted Nurse and Pharmacist Interventions
- 12 August 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 35 (10) , 1442-1445
Patient, Nurse, and Physician Perspectives on Personalized, Incremental Hemodialysis
An abstract is unavailable. This article is available as a PDF only.
- 12 August 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 35 (10) , 1442-1445
Patient, Nurse, and Physician Perspectives on Personalized, Incremental Hemodialysis
An abstract is unavailable. This article is available as a PDF only.
- 8 June 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (7) , 829-830
Inclement Weather and Dialysis Patients
- 8 June 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (7) , 829-830
Inclement Weather and Dialysis Patients
- 1 November 2022
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (11) , 1575-1576
Media Analysis of the Canadian Deemed Consent Policy
- 1 November 2022
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (11) , 1575-1576
Media Analysis of the Canadian Deemed Consent Policy
- 1 November 2022
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (11) , 1688-1690
Reducing the Risks of Home Dialysis Innovation and Uptake
- 1 November 2022
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (11) , 1688-1690
Reducing the Risks of Home Dialysis Innovation and Uptake
- 1 September 2022
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 33 (9) , 1797-1798
The Advancing American Kidney Health Initiative: The Challenge of Overcoming the Status Quo
- 1 September 2022
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 33 (9) , 1797-1798
The Advancing American Kidney Health Initiative: The Challenge of Overcoming the Status Quo
- 1 April 2022
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (4) , 591-593
Breaking the Barriers to Innovation in Kidney Care
- 1 April 2022
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (4) , 591-593
Breaking the Barriers to Innovation in Kidney Care
- 31 March 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (3) , 426-434
Patient-Reported Experiences after Acute Kidney Injury across Multiple Health-Related Quality-of-Life Domains
Key Points: Eighty-four percent of respondents reported that the AKI episode was very/extremely impactful on physical/emotional health. Fifty-seven percent reported being very/extremely concerned about AKI effects on work, and 67% were concerned about AKI effects on family. Future research should incorporate more comprehensive HRQoL measures and providers should give more information to patients about AKI. Background: Investigations of health-related quality of life (HRQoL) in AKI have been limited in number, size, and domains assessed. We surveyed AKI survivors to describe the range of HRQoL AKI-related experiences and examined potential differences in AKI effects by sex and age at AKI episode. Methods: AKI survivors among American Association of Kidney Patients completed an anonymous online survey in September 2020. We assessed: (1) sociodemographic characteristics; (2) effects of AKI—physical, emotional, social; and (3) perceptions about interactions with health care providers using quantitative and qualitative items. Results: Respondents were 124 adult AKI survivors. Eighty-four percent reported that the AKI episode was very/extremely impactful on physical/emotional health. Fifty-seven percent reported being very/extremely concerned about AKI effects on work, and 67% were concerned about AKI effects on family. Only 52% of respondents rated medical team communication as very/extremely good. Individuals aged 22–65 years at AKI episode were more likely than younger/older counterparts to rate the AKI episode as highly impactful overall (90% versus 63% younger and 75% older individuals; P=0.04), more impactful on family (78% versus 50% and 46%; P=0.008), and more impactful on work (74% versus 38% and 10%; P<0.001). Limitations of this work include convenience sampling, retrospective data collection, and unknown AKI severity. Conclusions: These findings are a critical step forward in understanding the range of AKI experiences/consequences. Future research should incorporate more comprehensive HRQoL measures, and health care professionals should consider providing more information in their patient communication about AKI and follow-up.
- 31 March 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (3) , 426-434
Patient-Reported Experiences after Acute Kidney Injury across Multiple Health-Related Quality-of-Life Domains
Key Points: Eighty-four percent of respondents reported that the AKI episode was very/extremely impactful on physical/emotional health. Fifty-seven percent reported being very/extremely concerned about AKI effects on work, and 67% were concerned about AKI effects on family. Future research should incorporate more comprehensive HRQoL measures and providers should give more information to patients about AKI. Background: Investigations of health-related quality of life (HRQoL) in AKI have been limited in number, size, and domains assessed. We surveyed AKI survivors to describe the range of HRQoL AKI-related experiences and examined potential differences in AKI effects by sex and age at AKI episode. Methods: AKI survivors among American Association of Kidney Patients completed an anonymous online survey in September 2020. We assessed: (1) sociodemographic characteristics; (2) effects of AKI—physical, emotional, social; and (3) perceptions about interactions with health care providers using quantitative and qualitative items. Results: Respondents were 124 adult AKI survivors. Eighty-four percent reported that the AKI episode was very/extremely impactful on physical/emotional health. Fifty-seven percent reported being very/extremely concerned about AKI effects on work, and 67% were concerned about AKI effects on family. Only 52% of respondents rated medical team communication as very/extremely good. Individuals aged 22–65 years at AKI episode were more likely than younger/older counterparts to rate the AKI episode as highly impactful overall (90% versus 63% younger and 75% older individuals; P=0.04), more impactful on family (78% versus 50% and 46%; P=0.008), and more impactful on work (74% versus 38% and 10%; P<0.001). Limitations of this work include convenience sampling, retrospective data collection, and unknown AKI severity. Conclusions: These findings are a critical step forward in understanding the range of AKI experiences/consequences. Future research should incorporate more comprehensive HRQoL measures, and health care professionals should consider providing more information in their patient communication about AKI and follow-up.